GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Common Stock

NAMS (NewAmsterdam Pharma Co NV) Common Stock : $13.44 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Common Stock?

NewAmsterdam Pharma Co NV's quarterly common stock increased from Jun. 2024 ($11.15 Mil) to Sep. 2024 ($11.44 Mil) and increased from Sep. 2024 ($11.44 Mil) to Dec. 2024 ($13.44 Mil).

NewAmsterdam Pharma Co NV's annual common stock increased from Dec. 2022 ($10.06 Mil) to Dec. 2023 ($10.17 Mil) and increased from Dec. 2023 ($10.17 Mil) to Dec. 2024 ($13.44 Mil).

NewAmsterdam Pharma Co NV Common Stock Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Common Stock Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
3.08 94.97 10.06 10.17 13.44

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.17 11.11 11.15 11.44 13.44

NewAmsterdam Pharma Co NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

NewAmsterdam Pharma Co NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Common Stock
Comparable Companies
SLNO HRMY APGE AGIO TVTX IDYA BCRX IRON JANX CGON VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.